Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
|Articles|October 11, 2021
AstraZeneca’s Long-Acting Antibody AZD7442 Reduced Risk of Severe or Fatal COVID-19
Author(s)Nina Cosdon
In the recent TACKLE phase 3 trial, AZD7442 significantly reduced the risk of developing severe COVID-19 or death, even among high-risk populations.
Advertisement
AstraZeneca's AZD7442 long-acting antibody (LAAB) combination achieved a significant reduction in severe COVID-19 or death, according to a
Upon receipt of positive high-level results from the TACKLE phase 3 COVID-19 treatment trial, AstraZeneca declared AZD7442 to be the only LAAB combination for COVID-19 prophylaxis and treatment.
Mene Pangalos, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, said, “These important results for AZD7442, our long-acting antibody combination, add to the growing body of evidence for use of this therapy in both prevention and treatment of COVID-19. An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months.”
At the trial’s primary endpoint, AZD7442 reduced the risk of severe COVID-19 or death (from any cause) by 50% as compared to the placebo. During this randomized, double-blind, placebo-controlled, multicenter trial, participants were given one 600 mg dose of AZD7442 via intramuscular injection.
Trial participants were 903 outpatients who had been symptomatic for seven days or fewer. Notably, 90% of participants enrolled in the TACKLE phase 3 trial were at high-risk of developing severe COVID-19, including those with comorbidities. The study recorded 18 events in the AZD7442 arm (18/407) and 37 in the placebo arm (37/415).
In an analysis of outpatients who received treatment within five days of symptoms, AZD7442 reduced the risk of severe or fatal COVID-19 by 67% as compared to the placebo, with nine events in the AZD7442 arm (9/253) and 27 in the placebo arm (27/251).
AZD7442 is a
AstraZeneca had previously
Advertisement
Related to this article
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Advertisement
Advertisement